IL17A and myeloid sarcoma: While T lymphocytes have long been regarded as central to MS pathogenesis, accumulating evidence underscores the pivotal role of B lymphocytes and dysregulated cytokine networks (e.g., Th17/IL-17 and NF-κB pathways) in driving disease initiation and progression.